Linde PLC vs Vir Biotechnology Inc. Common Stock — how do they compare? Linde PLC trades at $495.32 (market cap $226.85B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Linde PLC is far larger — about 126× Vir Biotechnology Inc. Common Stock's market cap, and Linde PLC pays a 1.3% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Linde PLC for 89 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| LIN | VIR | |
|---|---|---|
Market Cap | $226.85B | $1.80B |
Volume | 1,386,042 | 1,782,836 |
Sector | Basic Materials | Health |
52-Week High | $546.64 | $11.78 |
52-Week Low | $389.38 | $5.12 |
Typical Hold Time | 89 Days | 0 Days |
Enterprise Value | $249.97B | $1.36B |
Dividend Yield | 1.3% | — |
Signals from Pluang's Aura AI — not financial advice
Linde (LIN) trades at $492.11, up 0.98% today, near its 52-week high. The stock shows a bullish technical trend with strong fundamentals, including a 20.43% net income margin and consistent earnings beats. Recent news highlights its role in AI chip supply chains, while analyst consensus remains strongly positive with a $558.91 price target.
Outlook is favorable given robust profitability and growth in electronics end-markets, but risks include elevated valuation multiples and rising debt levels. The stock offers upside potential aligned with Wall Street optimism, though investors should weigh margin pressures and capital expenditure trends.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →